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Abstract 
We review the relationship between various types of mitochondrial DNA mutations and the prevalence as well as the pathobiochemi- 
cal and clinical features of mitochondrial diabetes mellitus. An A to G transversion mutation in the tRNA LeutUUR) gene is associated with 
diabetes in about 1.5% of the diabetic population in different countries and races. Phenotypically this type of mitochondrial diabetes is 
combined with deafness in more than 60% and is clinically distinguishable with respect o several characteristics from the two idiopathic 
forms of diabetes. The underlying pathomechanism is probably a delayed insulin secretion due to an impaired mitochondrial ATP 
production in consequence of the mtDNA defect. 
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While glucose intolerance is a symptom of various 
diseases, the term diabetes mellitus represents a genetically 
heterogenous group of disorders. Currently, diabetes is 
subdivided into two idiopathic forms, type 1 and type 2 
diabetes or IDDM and NIDDM on one side and a group of 
about 60 genetic syndromes on the other side, in which 
diabetes is only one symptom [1]. This combination with 
quite different genetic syndromes demonstrates that glu- 
cose intolerance can be a result of mutations at many 
different nuclear loci. Furthermore, it also illustrates that 
quite different pathogenetic mechanisms are associated 
with the symptom diabetes. Genetic factors contribute to 
the development of diabetes not only in several genetic 
syndromes but also in both idiopathic forms of diabetes 
mellitus (Table 1). Concordance rates in identical twins of 
near 100% and less than 40% for type 2 and type 1 
diabetes, respectively, clearly demonstrate a different ge- 
netic background for both forms. Furthermore, IDDM but 
not NIDDM shows an association to the HLA system. 
About 95% of diabetic Caucasians have HLA-DR 3 and/or 
4 indicating heterogeneity within the IDDM class. As 
about 50% of subjects in the nondiabetic Caucasian popu- 
lation also carry these HLA alleles HLA-DR 3 or DR 4 are 
not pathognomonic of IDDM. Several other, non-HLA 
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genes are supposed to contribute to the genetic predisposi- 
tion to IDDM. However, by comparing the risks of HLA- 
identical siblings to that of monozygotic twins one can 
estimate that HLA provides approximately 60-70% of the 
overall genetic susceptibility to IDDM [1]. The association 
with the HLA-system is accompanied with specific im- 
munologic phenomena in IDDM but not in NIDDM. 
1. Different types of mtDNA mutations are associated 
with diabetes 
Hints for the contribution of mtDNA to the develop- 
ment of diabetes [2-4] came from two different observa- 
tions: first, from epidemiological studies revealing a pre- 
dominantly maternal transmission of NIDDM [5-7]; sec- 
ondly, from observations that diabetes is frequently associ- 
ated with mitochondrial diseases [2,8,9]. The presence of 
diabetes has been noted in single patients with chronic 
progressive xternal ophthalmoplegia and the complete 
Kearns-Sayre syndrome carrying large mtDNA deletions 
and duplications [8-11]; in patients with Pearson's bone 
marrow pancreas yndrome [12]; with renal tubular dys- 
function [13,15] and in maternally inherited syndromes 
such as the MELAS syndrome (mitochondrial en- 
cephalomyopathy with lactic acidosis and stroke-like 
episodes) [14,19], rarely in those with the MERRF syn- 
drome (myoclonus epilepsy with ragged red fibers) [16,17]. 
254 K.-D. Gerbitz et aL / Biochimica et Biophysica Acta 1271 (1995) 253-260 
Table l 
Differences between IDDM, NIDDM and mitochondrial diabetes (MDM) 
IDDM NIDDM MDM 
Clinical characteristics thin obese 
ketosis prone ketosis resistant 
insulin dependent diet + drugs 
Onset childhood, adulthood mostly after 40 
Insulin response to glucose no or small response variable response 
Peripheral insulin effect yes resistant 
Glucagon secretion normal normal 
Genetic defect not known not known, mutations 
of glucokinase MODY 
Monozygotic twin studies concordance < 40% concordance > 90% ? 
HLA association yes no no 
Antibodies against: insulin yes no ? 
GAD yes no no 
islet cells yes no no 
lean 
no ketosis 
mostly insulin 
mostly before 40 
delayed response 
yes 
impaired 
mutations in mtDNA 
GAD = glutamic acid decarboxylase; MODY = maturity onset diabetes of the young. 
In 1992 two large pedigrees have been identified with 
diabetes and deafness, one harboring a unique 10.4 kb 
mtDNA deletion flanked by a 10 bp direct repeat at 
nucleotide positions (nps) 4389 and 14812 [3], and the 
other carrying the 'MELAS-associated' tRNA t~u(tJUR) mu- 
tation at np 3243 [4]. This latter observation has been 
Table 2 
tRNAt'eu(UUR)-3243 mutation and diabetes (update June 1994) 
Subjects Number of Number of Reference 
families (n) mutations, n (%) 
Familial IDDM 55 3 (5.5) Kadowaki et al. [24] 
17 1 (5.9) Jaksch et al. [27] 
90 0 Vionnet et al. [23] 
6 0 Katagiri et al. [25] 
200 0 Hattersley et al. [52] 
IDDM without 25 0 Odowara et al. [31] 
familial history 85 0 Kadowaki et al. [24] 
All IDDM 481 4 (0.8%) references above 
Slowly progressive IDDM 27 3 (11%) Oka [53] 
50 2 (4%) Bain [54] 
Familial NIDDM 267 5 (1.9%) Vionnet et al. [23] 
30 1 (3.3%) Awata et al. [22] 
100 2 (2%) Kadowaki et al. [24] 
68 1 (1.5%) Alcolado et al. [26] 
215 6 (2.8%) Hashiramoto [28] 
294 4 (1.4%) Katagiri et al. [25] 
210 5 (2.4%) Otabe et al. [32] 
Maternal NIDDM 65 2 (3.1%) Van den Ouweland et al. [29] 
28 3 (10.7) 't Hart et al. [30] 
12 1 (8.3%) Walker et al. [55] 
NIDDM and deafness 5 3 (60%) Kadowaki et al. [24] 
NIDDM without 35 0 Van den Ouweland et al. [4] 
familial history 150 0 Alcolado et al. [26] 
80 0 Van den Ouweland et al. [29] 
473 2 (0.5%) 't Hart et al. [30] 
550 5 (0.9%) Kadowaki et al. [32] 
89 3 (3.4%) Odowara et al. [31] 
300 0 Saker et al. [56] 
All NIDDM 2971 43 (1.4%) references above 
All IDDM and NIDDM 3529 52 (1.5%) al| references 
K.-D. Gerbitz et al. / Biochimica et Biophysica Acta 1271 (1995) 253-260 255 
tRNA Leu(UUR)mutat ions  and  d iabetes  
i t  C>T (3303) ! A'>G {3,902) ,~  A>G (32431 
O T>C (3250) l 
^>e (32511 ~ I
A>Gi (3252) I]1 C - G 
C>T (32341 ----1 II I G ^ C G 
C>T (~s)  ---1 I I I I  c III III 
A>G(3aS0)--IlIIII G T C G C 
i 
G=C 
T=-A 
T=A 
A=T 
A=T 
GF_C 
A=T 
T 
G 
C T 
I A T=A A 
A=T C 
A=T 
F---A = T 
T A 
T A A 
Fig. 1. tRNA Leu(vUR) mutations 
T A T 
TCTCC A 
II | II III Ul 
AGAGG C T T 
and diabetes. 
confirmed by many other reports even in pedigrees with 
different racial background [18-32]. The mitochondrial 
tRNA Leu(UuR) gene appears to be an etiological hot spot for 
mtDNA mutations. Ten disease-related mutations have 
been described, so far, in this gene which comprises about 
60% of all mitochondrial tRNA gene mutations [35] (Fig. 
1). Four of them have been described in single cases as 
being associated with diabetes and various other symp- 
toms. An A /G  transition at np 3252 was found in a patient 
with mitochondrial encephalomyopathy, pigmentary 
retinopathy, dementia nd hypothyroidism [33], an A /G  
mutation at np 3260 in single patients from a large pedi- 
gree with maternally inherited myopathy and cardiomyopa- 
thy [34] and a C /T  exchange at np 3256 in a patient with a 
MERFF-Iike syndrome [35]. 
2. Prevalence of the tRNALe"¢UUR)-3243 mutation among 
diabetics 
The overall prevalence of diabetes in the western Euro- 
pean countries lies between 3 and 6%. The contribution of 
the tRNA Leu(UUR) mutation at np 3243 has recently been 
investigated in the Netherlands, France, U.K., Germany 
and Japan (Table 2) [18-32]. The prevalence of mitochon- 
drial diabetes (MDM) seems not to be quite different 
between the different countries and races and is about 
1.5% among both idiopathic diabetes forms and about 2-5 
fold higher in cases with familial history of diabetes. Thus, 
the tRNALeu(UUR)-3243 mutation seems not to be a major 
cause of diabetes but contributes substantially to its overall 
incidence. The prevalence of MDM is therefore about 
0.06% in the general population, and this accounts, for 
example, for about 200000 diabetic patients in the Euro- 
pean community carrying this mutation. The occurrence 
may, in fact, even be higher since the amount of mutated 
mtDNA molecules is low in blood cells of some patients 
and hardly detectable when compared to fibroblasts, skele- 
tal muscles or epithelial cell from a mouthwash. Thus, 
screening for the heteroplasmic 3243 mutation as well as 
for duplication/deletion mutations on mtDNA extracted 
from blood may lead to an underestimation a d should, 
therefore, be preferentially performed on other cells. With 
the exception of the 3243 exchange mutations at other 
positions within the tRNA Leu(uURt gene have, so far, not 
been investigated systematically in large diabetic collec- 
tives. Only the 3271 mutation has been tested in a group of 
215 NIDDM with familial history but no respective case 
has been found [28]. A search for large duplication/dele- 
tion mutations has been performed by Alcolado et al. [26] 
Table 3 
Clinical symptoms in affected members from 45 families with diabetes and a mitochondrial tRNA Le"(UUR) mutation at np 3243 
Reference Number of Number of Clinical symptom 
families (n) affected members (n) 
DM D DM+D DM+D+N D+N 
or DM + M 
Van den Ouweland [4] 1 18 
Reardon [18] 1 13 
Gerbitz [ 19] 1 5 
Sue [20] 2 34 
Awata [22] 1 3 
Kadowaki [24] 22 57 
Katagiri [25] 4 19 
Van den Ouweland [29] 2 12 
't Hart [30] 2 13 
Suzuki [44] 7 17 
Hattersley [52] 2 8 
Sum 45 199 
Percentage 100 
1 6 11  - - 
4 2 7 - 
- - 3 2 - 
1 12  8 7 6 
1 - 2 - - 
17  4 28 8 - 
9 l 9 - - 
- 5 5 2 - 
1 1 11 - - 
3 - 7 7 - 
4 - 4 - - 
41 31 95 26 6 
21 15 48 13 3 
DM, diabetes mellitus; D, deafness; N, neurological symptoms; M, complete MELAS syndrome. 
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in 68 diabetic subjects with affected siblings and by Van 
den Ouweland et al. [29] in 45 NIDDM patients with 
maternal history without any positive findings. It is, thus 
far, not known to what degree further mtDNA point muta- 
tions contribute to the prevalence of diabetes. 
3. Phenotypic diversity of the tRNA Leu(vUm mutation in 
association with diabetes 
The tRNALe~(UUR)-3243 mutation was first described in 
MELAS patients and subsequently in patients with mater- 
nally inherited iabetes. Of the 199 affected members from 
45 families with diabetes and the tRNALeu(uuR)-3243 muta- 
tion so far described 48% suffered from diabetes and 
deafness, 13% had diabetes combined with deafness and 
other neurological symptoms including MELAS, 21% had 
only diabetes and 15% had deafness alone or combined 
with neurological alterations (3%) (Table 3). The high 
percentage of about 60% of the combination of both 
symptoms diabetes and deafness is striking. Due to the 
lack of examination for hearing abnormalities by the physi- 
cians the symptom hearing loss might be underestimated to 
some degree. The clinical variability of the 3243 mutation 
may not be restricted to these two disorders, as emphasized 
by the recent discovery of its presence in patients with 
cardiomyopathy [58] and an Alport-like syndrome (Jansen, 
J.J., Van den Ouweland, J.M.W., Van der Woude, F.J., 
Buijn, J.A., 't Hart, L.M., Maassen, J.A., Van Oost, B.A. 
and Lemkes, H.H.P.J., unpublished ata). The degree of 
heteroplasmy varies in different organs and tissues which 
might be responsible for the phenotypic diversity caused 
by the mutation [14]. Another theoretical explanation is 
that further nuclear or mitochondrial mutations may influ- 
ence the variability of the phenotype. While searching for 
such additional and synergistically functioning mutations 
we have found a transition at np 3398 in a family with the 
tRNALeu(UUR)-3243 mutation, suffering from diabetes, 
deafness and cardiomyopathy [19]. The 3398 mutation 
changes a highly conserved methionine to a threonine 
within the ND1 gene and is accompanied with a severe 
complex I deficiency. It was neither demonstrable in 143 
disease controls nor in 263 subjects with NIDDM of whom 
two also had the 3243 mutation, indicating that it is not 
diabetes-specific, but may contribute to the severity of the 
disease. 
A similar variant of the same ND1 codon, i.e. a base 
exchange at 3397 causing a methionine to alanine ex- 
change in this conserved region, was recently described by 
Shoffner et al. [36] in two patients with Parkinson and 
Alzheimer, respectively. Thus, these two mutations of the 
same ND1 codon and, in consequence, the respective 
amino acid exchanges possibly influence the phenotypic 
expression of quite different disorders in single patients. 
In the large Dutch pedigree with diabetes and deafness 
carrying the 3243 mutation, 45 mutations have been identi- 
fied by direct sequencing compared to the published Cam- 
bridge sequence [4]. However, besides 14 silent mutations 
in coding sequences and 29 known polymorphic sites, only 
the A to G transition at np 3243 was present in all 
members of the branch affected with diabetes while absent 
in another branch without diabetes. Furthermore, six addi- 
tional mutations present in this pedigree, which could 
confer the phenotype of the 3243 mutation to diabetes, 
were absent in three other pedigrees with diabetes and 
deafness, showing that the 3243 mutation alone associates 
with this particular phenotype [29]. 
4. Is the symptom diabetes in other genetic disorders 
related to mtDNA? 
Wolfram's yndrome (MIM 222300) is characterized by
diabetes insipidus, diabetes mellitus, optic atrophy and 
deafness giving rise to the acronym DIDMOAD. Other 
less common endocrinological and neurological bnormali- 
ties are hypogonadism, atonic bladder, ataxia, insomnia, 
seizures and a relatively high incidence of depression and 
psychotic behaviour. The syndrome has long been known 
as an autosomal recessive disorder. As most of the clinical 
phenotypes characteristic of the syndrome are consistent 
with an ATP supply defect, Bu and Rotter have recently 
proposed that the syndrome represents a mitochondrially 
mediated isease with either a nuclear or a mitochondrial 
genetic origin [37]. This hypothesis was confirmed by one 
report on a sporadic ase with a 7.6 kb deletion mutation 
of the mitochondrial genome [38]. We were not able to 
demonstrate mtDNA deletions or insertions (Van den 
Ouweland, J.M.W. and Maassen, J.A., unpublished obser- 
vation) or any disease-related alterations in all mitochon- 
drial tRNA genes from DIDMOAD patients [39]. Using 
SSCP, restriction analysis and direct sequencing of PCR 
Table 4 
LHON class II point mutation pattern in 7 Wolfram-syndrome suffering families 
Mutation site (np) Gene Nucleotide xchange AS exchange Conservation Controls (%) Families 
1 2 3 4 5 6 
% 
7 
3394 ND1 T /C  Y /H  high < 2 . . . . .  + - 
4136 ND1 A /G Y /C  moderate < 6 - - - + - - - 
4216 NDI T /C  Y /H  low 7-13 - - + + + + + 
4917 ND2 A /G D/N  high < 4 - - + - + + + 
14 
14 
71 
57 
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fragments we have extended our studies by investigating 
all the mitochondrially encoded respiratory chain subunits 
in index patients from seven families with complete and 
incomplete (without diabetes insipidus) Wolfram syn- 
drome. In five of these families we have detected a 
mutation pattern usually found in LHON families [40,41] 
Table 4. Our finding is confirmed by a recent report [42] 
on a young man suffering from incomplete Wolfram syn- 
drome and carrying the most common LHON mutation at 
np 11778. 
Thus, the symptom diabetes can be associated with 
three different ypes of mtDNA mutations: (i) deletion/du- 
plication mutations, (ii) biogenic mutations in the 
tRNA Leu(UuR) gene, and (iii) missense mutations in the ND 
subunit genes. 
In other words, the term 'mitochondrial diabetes melli- 
tus (MDM)' represents a heterogenous group at the mtDNA 
level. 
5. Possible pathomechanisms in MDM with respect to 
the current concept of insulin secretion 
The idiopathic forms of diabetes (IDDM and NIDDM) 
are characterized by quite different pathomechanisms. In 
IDDM the destruction of the pancreatic beta-cells leads to 
an absolute insulin deficiency of the whole organism. 
Increased glycogenolysis and gluconeogenesis a  well as a 
decrease in hepatic and peripheral glucose uptake by in- 
sulin-sensitive tissues are the respective results. NIDDM is 
usually characterized by normal or even elevated blood 
insulin concentrations, but also by a delayed insulin secre- 
tion after glucose stimulation as well as by a peripheral 
insulin resistance; i.e., a diminished responsiveness to 
insulin by muscle and adipose tissue. The latter symptom 
of an impaired insulin sensitivity in the periphery seems to 
be the primary, i.e., the first demonstrable defect in the 
development of NIDDM, but the exact mechanism is 
unknown and subject of worldwide extensive research [43]. 
Table I compares the clinical data of the two idiopathic 
forms of diabetes with those found in patients with dia- 
betes and the tRNALeu<UUR)-243 mutation indicating that 
mitochondrial diabetes is clinically as well as pathogeneti- 
cally a distinct entity. Thus, the 'mitochondrial diabetics' 
are mostly lean (in contrast o NIDDM), have usually no 
ketotic episodes (in contrast o IDDM) and are often to be 
treated with insulin. As demonstrated below, insulin secre- 
tion after a glucose load is delayed in patients with MDM, 
while they do not show significant resistance to insulin by 
muscle and adipose tissue (in contrast o NIDDM). The 
development of MDM seems not be accompanied by 
immunological phenomena such as antibodies directed 
against /3-cell structures or defined /3-cell peptides uch as 
glutamic acid decarboxylase (GAD). Furthermore, in con- 
trast to IDDM MDM seems not to be associated with 
certain HLA-subtypes. 
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Fig. 2. Oral glucose tolerance tests (100 g) in subjects with the 
tRNA I~u(UUR) mutation at np 3243 unaffected patients are from unrelated 
families with MELAS carrying the 3243 mutation but without any 
clinical symptoms [27]; data of diabetic subjects are taken from refer- 
ences [25,27,28]; mean _+ S.D. 
The exact way in which the tRNA Leu~UuR) mutation 
affects glucose homeostasis in MDM is unknown but 
preliminary studies using glucose tolerance tests and vari- 
ous euglycemic lamp techniques [23,27,28] suggest a 
defect in the secretory capacity of the beta-cells. As shown 
in Fig. 2, which combines our own data and those from the 
literature [25,57,27,28], diabetics with the tRNA Leu(UUR) 
mutation demonstrate an abnormal, i.e. delayed and insuf- 
ficient insulin and C-peptide response to a glucose load. 
Urinary C-peptide secretion is markedly decreased in these 
patients [24,44]. Euglycemic clamp studies [8,23,28] re- 
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vealed no or only moderate peripheral insulin resistance. 
Thus, MDM can tentatively be described as a type of 
diabetes which is caused by a secretory defect of the 
beta-cells due to a mtDNA mutation. In contrast o the 
impairment of secretion in NIDDM, which is restricted to 
the beta-cells, MDM seems to be additionally charac- 
terized by an impaired function of glucagon secreting 
alpha-cells, as recently demonstrated by arginine infusion 
tests in patients with the tRNA Leu(uUR) mutation [28]. 
We have subdivided into two groups the patients ub- 
jected to an oral glucose tolerance test- our own and those 
reported in the literature [23,27,28]: one group with dia- 
betes alone and the other with diabetes combined with 
deafness or other neurological symptoms. Fig. 2 clearly 
shows that the presence of further neurological symptoms 
is accompanied by a more severe derangement of the 
glucose balance, i.e., higher blood glucose concentrations 
and lower secretion profiles of insulin and C-peptide when 
compared to the diabetic group without deafness. Thus, it 
seems reasonable to assume that the severity of the pheno- 
type is dependent on the degree of heteroplasmy of the 
tRNALeu(UURL3243 mutation in different issues. 
The current concept of insulin secretion (Fig. 3; [45,46]) 
involves several steps, starting with glucose uptake into the 
/3-cell by a glucose transporter (Glut 2), followed by 
phosphorylation by glucokinase. Neither steps are rate- 
limiting. Recent studies have demonstrated that cytosolic 
NADH produced along the glyceraldehyde hydrogenase 
reaction mediates the glucose signal [46]. As NADH can- 
not enter the mitochondrium the reducing equivalents are 
transferred into the mitochondrium via shuttle mecha- 
nisms, the oxaloacetate-malate cycle, which works by 
transamination, and the dihydroxyacetone phosphate- 
glycerol phosphate cycle [46]. The reduction of the mito- 
chondrial pyridine nucleotide and ravin pool is followed 
by stimulation of the electron transport chain and hyper- 
polarization of the mitochondrial membrane as well as by 
an increase in the ATP production rate and an increase in 
intracellular ATP/ADP ratio. This leads to a closure of 
ATP dependent potassium channels (KAT P channels), a 
depolarization of the beta-cell membrane, the opening of 
voltage-activated calcium channels, and an increase of the 
intracellular calcium concentration which promotes the 
secretion of insulin [45]. This partly hypothetical concept 
is confirmed by several observations. First, the rate of 
oxygen consumption parallels the increase of glucose con- 
centration in isolated islets of Langerhans [47,48]. Sec- 
ondly, agents which inhibit mitochondrial oxidative 
metabolism also produce marked activation of the KAT P 
channels and, vice versa, blocker of KAT p currents pro- 
mote insulin secretion [45,46]. For example, 2-ketoiso- 
caproic acid, a deamination product of leucine which is 
directly metabolized via the Krebs cycle, increases oxygen 
consumption in isolated /3-cells, inhibits KAT p channel 
activity [49] and also acts as a potent insulin secretagogue 
[45]. The exact mechanism by which glucose metabolism 
in beta-cells is coupled to insulin secretion remains to be 
established. However, mitochondrial oxidative ATP 
turnover seems to play an important role. If so, one would 
expect that mutations of the mtDNA which impair the 
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Fig. 3. Current concept of insulin secretion by pancreatic beta-cells; cheme modified according toreferences [45], [46] and [59]. Abbreviations: G-6-P, 
glucose 6-phosphate; GAP, glyceraldehyde-3-phosphate; MA, malate; PGP, 1,3-bisphosphoglycerate; GLU, glutamate; ASP, aspartate; OA, oxaloacetate; 
KG, a-ketoglutarate; DAP, dihydroxyacetonephosphate; GLP, glycerol phosphate; C I, complex I (NADH-ubiquinone oxidoreductase); C If, complex II 
(succinate-ubiquinone oxidoreductase); C III, complex III (ubiquinol; ferricytochrome-c oxidoreductase); C IV, complex IV (cytochrome-c oxidase); C V, 
complex V (ATP synthase). 
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exact function of the oxidative phosphorylation, i.e. ATP- 
synthesis, will result in a derangement of the specific 
function of the beta-cell, i.e. insulin secretion. 
6. mtDNA and other endocrinopathies 
Several endocrine abnormalities have recently been de- 
scribed in 21 patients with chronic progressive xternal 
ophthalmoplegia (CPEO) [9]. As far as tested most of these 
patients carried a mtDNA deletion [50]. 8/21 had impaired 
glucose tolerance or diabetes, 5/15 investigated patients 
with CPEO had growth hormone deficiency, 2/19 had 
hypoparathyroidism, 4/17 showed follicle stimulating hor- 
mone deficiency and 6/19 had hypogonadism. In a recent 
review on endocrine abnormalities in KSS 20% of the 
patients had gonadal dysfunction and 13% diabetes melli- 
tus with or without other endocrine symptoms [60]. Thus 
mitochondrial myopathies presenting with CPEO seem to 
be much more often associated with endocrinopathies than 
the general population. In about one half of the cases 
reported in the literature the endocrine abnormalities pre- 
cede the ocular myopathy. Therefore, unclear en- 
docrinopathies should be subjected to investigation of the 
mtDNA in order to elucidate the underlying pathomecha- 
nism. Recently it has been demonstrated that also the 
physiologically altered function of the human ovary gland 
during menopausis accompanied by an accumulation of 
deleted mtDNA in the ovary [51]. 
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